These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 39023168)

  • 1. Engineered CAR-NK cells with tolerance to H2O2 and hypoxia can suppress postoperative relapse of triple-negative breast cancers.
    Liu Y; Chen J; Tian J; Hao Y; Ma X; Zhou Y; Feng L
    Cancer Immunol Res; 2024 Jul; ():. PubMed ID: 39023168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Injectable Puerarin Depot Can Potentiate Chimeric Antigen Receptor Natural Killer Cell Immunotherapy Against Targeted Solid Tumors by Reversing Tumor Immunosuppression.
    Liu Y; Hao Y; Chen J; Chen M; Tian J; Lv X; Zhang Y; Ma X; Zhou Y; Feng L
    Small; 2024 Jun; 20(25):e2307521. PubMed ID: 38212279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.
    Liu Y; Zhou Y; Huang KH; Fang X; Li Y; Wang F; An L; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
    Cell Prolif; 2020 Aug; 53(8):e12858. PubMed ID: 32592435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer.
    Raftery MJ; Franzén AS; Radecke C; Boulifa A; Schönrich G; Stintzing S; Blohmer JU; Pecher G
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models.
    Yang M; Guan T; Chen CF; He LF; Wu HM; Zhang RD; Li Y; Lin YC; Zeng H; Wu JD
    J Immunother; 2023 Oct; 46(8):285-294. PubMed ID: 37584622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer.
    Hu Z
    Sci Rep; 2020 Feb; 10(1):2815. PubMed ID: 32071339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the Interplay of CAR-NK Cells and Triple-Negative Breast Cancer: Insights from Computational Modeling.
    Arabameri A; Arab S
    Bull Math Biol; 2024 Jan; 86(2):20. PubMed ID: 38240892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
    Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
    Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells.
    Marrufo AM; Mathew SO; Chaudhary P; Malaer JD; Vishwanatha JK; Mathew PA
    Am J Cancer Res; 2018; 8(6):1050-1063. PubMed ID: 30034942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity.
    Ligtenberg MA; Mougiakakos D; Mukhopadhyay M; Witt K; Lladser A; Chmielewski M; Riet T; Abken H; Kiessling R
    J Immunol; 2016 Jan; 196(2):759-66. PubMed ID: 26673145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Exercise Increases NK Cell Mitochondrial Respiration and Cytotoxicity against Triple-Negative Breast Cancer Cells under Hypoxic Conditions.
    Cho E; Stampley J; Wall R; Matthews R; Zunica E; Brown JC; Johannsen NM; Irving BA; Spielmann G
    Med Sci Sports Exerc; 2023 Dec; 55(12):2132-2142. PubMed ID: 37436930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers.
    Ba H; Dai Z; Zhang Z; Zhang P; Yin B; Wang J; Li Z; Zhou X
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Injectable Epigenetic Autophagic Modulatory Hydrogel for Boosting Umbilical Cord Blood NK Cell Therapy Prevents Postsurgical Relapse of Triple-Negative Breast Cancer.
    Gong Y; Chen W; Chen X; He Y; Jiang H; Zhang X; Pan L; Ni B; Yang F; Xu Y; Zhang Q; Zhou L; Cheng Y
    Adv Sci (Weinh); 2022 Aug; 9(23):e2201271. PubMed ID: 35712750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.
    Chen X; Han J; Chu J; Zhang L; Zhang J; Chen C; Chen L; Wang Y; Wang H; Yi L; Elder JB; Wang QE; He X; Kaur B; Chiocca EA; Yu J
    Oncotarget; 2016 May; 7(19):27764-77. PubMed ID: 27050072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
    Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
    Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
    Eitler J; Rackwitz W; Wotschel N; Gudipati V; Murali Shankar N; Sidorenkova A; Huppa JB; Ortiz-Montero P; Opitz C; Künzel SR; Michen S; Temme A; Loureiro LR; Feldmann A; Bachmann M; Boissel L; Klingemann H; Wels WS; Tonn T
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
    Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
    Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-κB/Icam1 signaling.
    Zhou M; Chen M; Shi B; Di S; Sun R; Jiang H; Li Z
    Mol Ther; 2022 Nov; 30(11):3379-3393. PubMed ID: 35927951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies.
    He B; Mai Q; Pang Y; Deng S; He Y; Xue R; Xu N; Zhou H; Liu X; Xuan L; Li C; Liu Q
    Front Immunol; 2023; 14():1130442. PubMed ID: 37207215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
    Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E
    Front Immunol; 2020; 11():581468. PubMed ID: 33193388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.